Prademagene zamikeracel, sold under the brand name Zevaskyn, is an autologous cell-based gene therapy for the treatment of recessive dystrophic epidermolysis bullosa.
Legal status Prademagene zamikeracel was approved for medical use in the United States in April 2025. Names Prademagene zamikeracel is the international nonproprietary name. Prademagene zamikeracel is sold under the brand name Zevaskyn. == References ==